| pubmed-article:2753072 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2753072 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:2753072 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:2753072 | lifeskim:mentions | umls-concept:C0280606 | lld:lifeskim |
| pubmed-article:2753072 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:2753072 | lifeskim:mentions | umls-concept:C0412467 | lld:lifeskim |
| pubmed-article:2753072 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2753072 | pubmed:dateCreated | 1989-9-1 | lld:pubmed |
| pubmed-article:2753072 | pubmed:abstractText | The pharmacokinetics of high-dose busulphan was studied in adult patients with acute myeloblastic leukaemia after oral doses of 1 mg.kg-1 every 6 h for 4 days. The mean steady-state plasma concentration was 1080 ng/ml-1 during the treatment. Individual steady-state concentrations after the last dose on average were 32% lower than those predicted from total AUC measurements following the first dose. Mean elimination half-life in plasma was 2.3 h after the last dose and 3.4 h after the first dose which suggests that busulfan may increase its own metabolic rate on repeated treatment. The cerebrospinal fluid/plasma concentration ratio of busulphan was 1.3. Busulphan showed insignificant protein binding in plasma (7.4%). About 2% of the dose was excreted unchanged in the urine. For the first time sulpholane, 3-hydroxysulpholane and tetrahydrothiophene 1-oxide were identified as urinary metabolites of busulphan in man. | lld:pubmed |
| pubmed-article:2753072 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2753072 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2753072 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2753072 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2753072 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2753072 | pubmed:issn | 0031-6970 | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:EhrssonHH | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:EhrneboMM | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:WallisRR | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:HassanMM | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:TöttermanTT | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:EksborgSS | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:SimonssonBB | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:ObergGG | lld:pubmed |
| pubmed-article:2753072 | pubmed:author | pubmed-author:SmedmyrBB | lld:pubmed |
| pubmed-article:2753072 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2753072 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:2753072 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2753072 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2753072 | pubmed:pagination | 525-30 | lld:pubmed |
| pubmed-article:2753072 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:meshHeading | pubmed-meshheading:2753072-... | lld:pubmed |
| pubmed-article:2753072 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2753072 | pubmed:articleTitle | Pharmacokinetic and metabolic studies of high-dose busulphan in adults. | lld:pubmed |
| pubmed-article:2753072 | pubmed:affiliation | Karolinska Pharmacy, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:2753072 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2753072 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
